Navigation Links
Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT
Date:11/9/2011

SAN FRANCISCO (Nov. 9, 2011; 12:50 p.m.) Late breaking clinical trial results from testing of cangrelor, an investigational intravenous antiplatelet, showed patients can be "bridged" from the time that their physicians stop their oral antiplatelet drugs until they undergo cardiac surgery. Study results demonstrated cangrelor maintained target levels of platelet inhibition known to be associated with a low risk of thrombotic events, such as stent thrombosis, vs. placebo. The BRIDGE Trial results were presented here today at the Cardiovascular Research Foundation (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) conference.

"Patients with coronary stents require drugs that block platelets that can stick to their stents and cause clots. When these patients require surgery, the oral drugs must be stopped days in advance to wear off and reduce the risk of surgical bleeding; however, this puts them at an increased risk of thrombotic events," said Eric Topol, MD, cardiologist and chief academic officer at Scripps Health and BRIDGE Trial primary investigator. "With nothing available that blocks platelets and then goes away quickly, we are between the rock of thrombosis and the hard place of surgical bleeding."

BRIDGE results showed 99 percent of cangrelor-treated patients maintained target levels of platelet inhibition for all time points measured over the bridging period compared to 19 percent of placebo patients (p<0.001). The primary safety measure demonstrated no significant excess in surgical bleeding complications (data below).

The results were presented by Dominick J. Angiolillo, MD, PhD, medical director, cardiovascular research program at the University of Florida College of Medicine Jacksonville, "BRIDGE results support the hypothesis that intravenous cangrelor may be a feasible and well tolerated management strategy in patients who require prolonged platelet P2Y12 inhibition after thienopyridine discontinuation pr
'/>"/>

Contact: Rebecca Hollins
rebecca.hollins@themedco.com
973-290-6081
The Medicines Company
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Scripps research team solves structure of beneficial virus
2. Scripps research team sheds light on immune system suppression
3. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
4. Scripps research scientists identify compounds for stem-cell production from adult cells
5. Scripps research scientists identify blood component that turns bacteria virulent
6. Scripps research team defines new painkilling chemical pathway
7. Dolphin population stunted by fishing activities, Scripps/NOAA study finds
8. Scripps Research scientists shed light on how DNA is unwound so that its code can be read
9. Scripps scientists develop first examples of RNA that replicates itself indefinitely
10. Scripps scientists create first crystal structure of an intermediate particle in virus assembly
11. Historical photographs expose decline in Floridas reef fish, new Scripps study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT
(Date:1/22/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a ... the recent success of the Wocket™ smart wallet at CES 2015 in ... was named as one of the "11 Hot Products at CES" in ... At CES So Far" by Newseveryday.com and "The top 10 gadgets from ...
(Date:1/22/2015)... , Europe,s most prestigious innovation ... to present a video retrospective of the most exciting and innovative ... Toumazou and Sophie Wilson   A different ...   Starting on 22 January 2015 on   http://www.epo.org/european-inventor   ...
(Date:1/22/2015)... Infinisource has launched its new NXG series of time clocks ... a higher standard for collecting attendance and labor data and ... installation, touch screen interface and seamless connection to cloud-based iSolved, ... solution for the small to mid-size employer. The ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3Infinisource's NXG series sets new time clock standard 2
... Female harbor seal pups whose blubber falls below average levels ... death, even if they get enough fat in their diets ... American Physiological Society and presented at Experimental Biology 2006. , ... when captured from the wild continued to gain weight and ...
... transplantation performed in France spread around the world, plastic ... first full facial transplantation a reality. , In the ... surgeons demonstrated how to successfully complete a full facial ... the March issue of Plastic and Reconstructive Surgery® (PRS), ...
... likely to have poor outcomes following a living-donor liver ... dye was eliminated by the liver shortly after surgery ... a reliable indicator of the outcome of the procedure. ... the dye, making it particularly useful in treating transplant ...
Cached Biology News:Alaska seal pup diet may hold key to decline of population 2Alaska seal pup diet may hold key to decline of population 3Alaska seal pup diet may hold key to decline of population 4Plastic surgeons countdown first full facial transplantation 2Predicting successful outcomes in living-donor liver transplants 2Predicting successful outcomes in living-donor liver transplants 3
(Date:2/27/2015)... GERMANTOWN, Md. and SUMMERLAND, British ... Corporation (NYSE: XON ), a leader ... an agreement to acquire  Okanagan Specialty Fruits (OSF), ... apple , the world,s first non-browning apple. Through ... trees yielding fruit that is more appetizing and convenient ...
(Date:2/27/2015)... DUBLIN , Feb. 27, 2015 Research and Markets ... the "Global Market Report of Trypsin" report to ... Trypsin (CAS 9002-07-7) aims at providing comprehensive data on Trypsin ... Asia , North America , ... trends, pays close attention to Trypsin This report ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited (ASX:BNO, ... DisrupTOR-1 trial of BNC105 in patients with metastatic renal ... Orlando, Florida . The data will be ... City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 as ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Global Market Report of Trypsin 2014-2018 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6
... million in 2008 on target; Potential label ... expansion could further drive sales, ... CTIC) reported financial results for the quarter,ended June 30, 2008. ... for the second quarter of 2007 due primarily to sales,of ...
... Aug. 15 XTL,Biopharmaceuticals Ltd. (Nasdaq: XTLB ... Staff Deficiency Letter from The Nasdaq Stock Market,("Nasdaq") ... the audit,committee composition requirements of Nasdaq Marketplace Rule ... comprised of at least,three independent directors., XTL, ...
... Increases 34% Driving Record Profitability, HARBIN, China, ... (the "Company") (OTC Bulletin Board: CKGT), a,vertically integrated ... cactus-based consumer products in China, announced today record,second ... 2008. The Company,reported revenue of $5.0 million, a ...
Cached Biology Technology:Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 2Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 3Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 4Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 5Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 6Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results 7XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition 2XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition 3China Kangtai Cactus Biotech Announces Record Second Quarter Results 2China Kangtai Cactus Biotech Announces Record Second Quarter Results 3